News

MENLO PARK, CA, June 22, 2023— LamdaGen Corporation, an emerging diagnostic technology company with a powerful, plasmonic platform for rapid diagnostic/detection testing, is pleased to announce the members of its

The aim of this brief is to provide a description of the optical properties of LamdaGen’s gold plasmonic sensor surfaces and compare them with the optical properties of gold (Au)

LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the Indian Patent Office has granted and

MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the

MENLO PARK, CA, January 8, 2021—  LamdaGen Corporation, a developer of  plasmonic  biosensor systems for diagnostics, announced the Japanese Patent Office has given Official Notice of Allowance to its patent

LamdaGen’s LAuRA digital platform is a field deployable rapid immuno-based testing system focused on high-sensitivity detection of infectious disease protein markers. The Point of Care (POC) platform is capable of performing

MENLO PARK, CA, October 14, 2020—  LamdaGen Corporation, a developer of  plasmonic  biosensor systems for diagnostics, announced the European Patent Office (EPO) has granted its patent application entitled “Digital LSPR

Figure Caption Top Tier: The viral load of SARS-CoV-2 in patients charted as determined in hospital settings across several regions of the world.[1-4] In three studies, the pool includes a limited

Menlo Park, CA and San Diego, CA – LamdaGen Corporation and Arisan Therapeutics announced today they have been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant